PLCE1 and cancer: Phospholipase Cε (PLCε) has been shown to augment inflammation and inflammation-associated carcinogenesis by inducing proinflammatory cytokine expression through activation of nuclear factor-κB (NF-κB), making it a candidate molecular target for development of anti-inflammatory and cancer-preventive agents.